Inspire Medical Systems (NYSE:INSP) Issues Quarterly Earnings Results

Key Points

• EPS and guidance beat: Inspire reported Q (quarter) EPS of $0.10 versus a consensus loss of ($0.28) and revenue of $204.6M (vs. $200.0M est.), and updated FY2026 guidance to 0.75–1.25 EPS.
• Shares traded down to $54.77 midday (‑$1.93) on elevated volume; the company has a $1.58B market cap, a P/E of 11.0, and 50/200-day moving averages of $56.73 and $79.64 respectively.
• Institutions own 94.91% of the stock with large recent purchases by Wellington, Morgan Stanley, Wasatch and Deerfield, while analysts are mostly neutral (13 Holds) with a consensus target of $101.41.

Inspire Medical Systems (NYSE:INSP - Get Free Report) announced its quarterly earnings data on Monday. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38, FiscalAI reports. The company had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. Inspire Medical Systems updated its FY 2026 guidance to 0.750-1.250 EPS.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP traded down $1.93 during midday trading on Monday, hitting $54.77. The company's stock had a trading volume of 1,586,372 shares, compared to its average volume of 1,178,608. Inspire Medical Systems has a 1-year low of $48.30 and a 1-year high of $163.35. The firm's fifty day moving average price is $56.73 and its 200-day moving average price is $79.64. The firm has a market cap of $1.58 billion, a P/E ratio of 11.00, a P/E/G ratio of 2.92 and a beta of 0.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP acquired a new position in Inspire Medical Systems during the 4th quarter valued at about $203,929,000. Wasatch Advisors LP boosted its stake in Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company's stock valued at $212,095,000 after purchasing an additional 110,288 shares during the period. Morgan Stanley boosted its stake in Inspire Medical Systems by 179.5% during the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company's stock valued at $116,188,000 after purchasing an additional 809,121 shares during the period. Deerfield Management Company L.P. boosted its stake in Inspire Medical Systems by 648.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company's stock valued at $77,739,000 after purchasing an additional 907,694 shares during the period. Finally, State Street Corp boosted its stake in Inspire Medical Systems by 2.3% during the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company's stock valued at $133,780,000 after purchasing an additional 22,843 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

INSP has been the subject of several recent analyst reports. Wells Fargo & Company set a $70.00 price objective on shares of Inspire Medical Systems and gave the stock an "equal weight" rating in a report on Thursday, February 12th. Jefferies Financial Group decreased their price target on shares of Inspire Medical Systems from $81.00 to $66.00 and set a "hold" rating for the company in a report on Thursday, February 12th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $56.00 price target on shares of Inspire Medical Systems in a report on Tuesday, April 14th. Zacks Research lowered shares of Inspire Medical Systems from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 14th. Finally, UBS Group set a $67.00 price target on shares of Inspire Medical Systems in a report on Friday, February 13th. Five analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $101.41.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.